Skip to main content

B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study.

Publication ,  Journal Article
Haynes, BF; Kelsoe, G; Harrison, SC; Kepler, TB
Published in: Nat Biotechnol
May 7, 2012

Failure of immunization with the HIV-1 envelope to induce broadly neutralizing antibodies against conserved epitopes is a major barrier to producing a preventive HIV-1 vaccine. Broadly neutralizing monoclonal antibodies (BnAbs) from those subjects who do produce them after years of chronic HIV-1 infection have one or more unusual characteristics, including polyreactivity for host antigens, extensive somatic hypermutation and long, variable heavy-chain third complementarity-determining regions, factors that may limit their expression by host immunoregulatory mechanisms. The isolation of BnAbs from HIV-1-infected subjects and the use of computationally derived clonal lineages as templates provide a new path for HIV-1 vaccine immunogen design. This approach, which should be applicable to many infectious agents, holds promise for the construction of vaccines that can drive B cells along rare but desirable maturation pathways.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Nat Biotechnol

DOI

EISSN

1546-1696

Publication Date

May 7, 2012

Volume

30

Issue

5

Start / End Page

423 / 433

Location

United States

Related Subject Headings

  • Vaccines
  • Neutralization Tests
  • Mutation
  • Immunogenetics
  • Humans
  • HIV-1
  • HIV Antibodies
  • Epitopes
  • Drug Design
  • Dimerization
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Haynes, B. F., Kelsoe, G., Harrison, S. C., & Kepler, T. B. (2012). B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol, 30(5), 423–433. https://doi.org/10.1038/nbt.2197
Haynes, Barton F., Garnett Kelsoe, Stephen C. Harrison, and Thomas B. Kepler. “B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study.Nat Biotechnol 30, no. 5 (May 7, 2012): 423–33. https://doi.org/10.1038/nbt.2197.
Haynes BF, Kelsoe G, Harrison SC, Kepler TB. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol. 2012 May 7;30(5):423–33.
Haynes, Barton F., et al. “B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study.Nat Biotechnol, vol. 30, no. 5, May 2012, pp. 423–33. Pubmed, doi:10.1038/nbt.2197.
Haynes BF, Kelsoe G, Harrison SC, Kepler TB. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol. 2012 May 7;30(5):423–433.

Published In

Nat Biotechnol

DOI

EISSN

1546-1696

Publication Date

May 7, 2012

Volume

30

Issue

5

Start / End Page

423 / 433

Location

United States

Related Subject Headings

  • Vaccines
  • Neutralization Tests
  • Mutation
  • Immunogenetics
  • Humans
  • HIV-1
  • HIV Antibodies
  • Epitopes
  • Drug Design
  • Dimerization